M. F. Krummel and M. M. Davis, Dynamics of the immunological synapse: finding, establishing and solidifying a connection, Current Opinion in Immunology, vol.14, issue.1, pp.66-74, 2002.
DOI : 10.1016/S0952-7915(01)00299-0

L. Roquet, M. Briant-longuet, T. Cérutti, and . Chardès, Biological activities on T lymphocytes of a baculovirus-expressed chimeric recombinant IgG1 antibody with specificity for the CDR3-like loop on the D1 domain of the CD4 molecule, Clin. Immunol, vol.119, pp.38-50, 2006.

S. Troadec, M. Chentouf, B. Nguyen, M. Cérutti, D. Olive et al., In vitro anti-tumoral mechanisms of baculovirus-expressed recombinant anti-CD4 antibody 13B8.2 on T cell lymphomas, J. Immunother, pp.30-190, 2007.

M. Chentouf, S. Ghannam, C. Bès, S. Troadec, M. Cérutti et al., Recombinant anti-CD4 antibody 13B8.2 blocks membrane-proximal events by excluding the Zap70 molecule and downstream targets SLP-76, PLC gamma 1, and Vav-1 from the CD4- segregated Brij 98 detergent-resistant raft domains, J. Immunol, pp.179-409, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00170828

. Chardès, The lipid-modulating effects of a CD4-specific recombinant antibody correlate with ZAP-70 segregation outside membrane rafts, Immunol. Lett, vol.133, pp.62-69, 2010.

A. Poggi, C. Bottino, M. R. Zocchi, G. Pantaleo, E. Ciccone et al., CD3+ WT31-peripheral T lymphocytes lack T44 (CD28), a surface molecule involved in activation of T cells bearing the alpha/beta heterodimer, Eur. J. Immunol, pp.17-1065, 1987.

O. Gaide, F. Martinon, O. Micheau, D. Bonnet, M. Thome et al., Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NFkappaB activation, FEBS Lett, pp.496-121, 2001.

O. Gaide, B. Favier, D. F. Legler, D. Bonnet, B. Brissoni et al., CARMA1 is a critical lipid raft???associated regulator of TCR-induced NF-??B activation, Nature Immunology, vol.3, issue.9, pp.836-843, 2002.
DOI : 10.1038/ni830

J. M. Rottapel and . Penninger, The MAGUK family protein CARD11 is essential for lymphocyte activation, Immunity, vol.18, pp.763-775, 2003.

T. Egawa, B. Albrecht, B. Favier, M. Sunshine, K. Mirchandani et al., Littman Requirement for CARMA1 in antigen receptor-induced NF-kappa B activation and lymphocyte proliferation, Curr. Biol, pp.13-1252, 2003.

T. Che, Y. You, D. Wang, M. J. Tanner, V. M. Dixit et al., MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-kappaB activation, J Biol Chem, pp.279-15870, 2004.

S. C. Bunnell, Determining the Destiny of NF-?? B after TCR Ligation: It's CARMA1, Molecular Interventions, vol.2, issue.6, pp.356-360, 2002.
DOI : 10.1124/mi.2.6.356

J. Nuñez, J. Bertin, and X. Lin, A requirement for CARMA1 in TCR-induced NF-kappa B activation, Nat. Immunol, vol.3, pp.830-835, 2002.

B. Mani, C. Pau, C. Devaux, G. Granier, T. Devauchelle et al., The chimeric mousehuman anti-CD4 Fab 13B8.2 expressed in baculovirus inhibits both antigen presentation and HIV-1 promoter activation, Hum. Antibodies, vol.10, pp.67-76, 2001.

Q. Li, A. Lau, T. J. Morris, L. Guo, C. B. Fordyce et al., A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: analysis by, pp.216-228, 2005.

S. Bolte and F. P. Cordelières, A guided tour into subcellular colocalization analysis in light microscopy, Journal of Microscopy, vol.56, issue.3, pp.213-232, 2006.
DOI : 10.1016/S0014-5793(03)00521-0

URL : https://hal.archives-ouvertes.fr/hal-00132481

X. Wang and . Lin, Phosphorylation of CARMA1 plays a critical role in T Cell receptormediated NF-kappaB activation, Immunity, vol.23, pp.575-585, 2005.

K. Sommer, B. Guo, J. L. Pomerantz, A. D. Bandaranayake, M. E. Moreno-garcía et al., Phosphorylation of the CARMA1 linker controls NF-kappaB activation, Immunity, pp.23-561, 2005.

. Rawlings, Serine 649 Phosphorylation within the Protein Kinase C-Regulated Domain Down-Regulates CARMA1 Activity in Lymphocytes, J. Immunol, vol.183, pp.7362-7370, 2009.

A. Badreddine, J. Bielawska, G. S. Usta, and . Dbaibo, Ceramide inhibits IL-2 production by preventing protein kinase C-dependent NF-kappaB activation: possible role in protein kinase Ctheta regulation, J. Immunol, pp.173-3193, 2004.

. Mano, High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays, Leukemia, pp.22-1891, 2008.

Y. Hosokawa, H. Suzuki, Y. Suzuki, R. Takahashi, and M. Seto, Antiapoptotic Function of Apoptosis Inhibitor 2-MALT1 Fusion Protein Involved in t(11;18)(q21;q21) Mucosa-Associated Lymphoid Tissue Lymphoma, Cancer Research, vol.64, issue.10, pp.3452-3457, 2004.
DOI : 10.1158/0008-5472.CAN-03-3677

. Schwaller, MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells, Blood, pp.105-2891, 2005.

M. T. Tian, G. Gonzalez, B. Scheer, and A. L. Defranco, Bcl10 can promote survival of antigen-stimulated B lymphocytes, Blood, vol.106, issue.6, pp.2105-2112, 2005.
DOI : 10.1182/blood-2004-04-1248

A. Oshiro, H. Tagawa, K. Ohshima, K. Karube, N. Uike et al., Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma, Blood, vol.107, issue.11, pp.4500-4507, 2006.
DOI : 10.1182/blood-2005-09-3801

B. D. Medoff, B. Seed, R. Jackobek, J. Zora, Y. Yang et al., CARMA1 Is Critical for the Development of Allergic Airway Inflammation in a Murine Model of Asthma, The Journal of Immunology, vol.176, issue.12, pp.7272-7277, 2006.
DOI : 10.4049/jimmunol.176.12.7272

I. A. Auer, R. D. Gascoyne, J. M. Connors, F. E. Cotter, T. C. Greiner et al., 18)(q21;q21) is the most common translocation in MALT lymphomas, Annals of Oncology, vol.8, issue.10, pp.979-985, 1997.
DOI : 10.1023/A:1008202303666

M. C. Sempere, V. R. Fanjul, I. Sánchez-pérez, and R. Perona, The role of the NF??B signalling pathway in cancer, Clinical and Translational Oncology, vol.25, issue.3, pp.143-147, 2008.
DOI : 10.1007/s12094-008-0171-3

M. Cavo, Proteasome inhibitor bortezomib for the treatment of multiple myeloma, Leukemia, vol.106, issue.8, pp.1341-1352, 2006.
DOI : 10.1038/sj.leu.2404278

E. Alinari, A. Derenzini, E. De-vivo, S. Sabattini, M. Pileri et al., Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma, J. Clin. Oncol, pp.25-4293, 2007.

. Kim, Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma, Ann. Oncol, vol.19, pp.2079-2083, 2008.

C. A. Sarmiento, R. Rosen, and . Narayanan, Antisense inhibition of the p65 subunit of NFkappa B blocks tumorigenicity and causes tumor regression, Proc. Natl. Acad. Sci

A. L. Kasinski and F. J. Slack, Potential microRNA therapies targeting Ras, NFkappaB and p53 signaling, Curr. Opin. Mol. Ther, vol.12, pp.147-157, 2010.

D. De-stefano, G. De-rosa, and R. Carnuccio, NFkappaB decoy oligonucleotides, Curr. Opin. Mol. Ther, vol.12, pp.203-213, 2010.

V. S. Yang, W. Iotzova, J. Clarke, Y. Strnad, F. C. Qiu et al., BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice, J. Biol. Chem, pp.278-1450, 2003.

V. Pien, J. Palombella, and . Adams, Novel IKK inhibitors: beta-carbolines